Literature DB >> 11421589

Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice.

D E Dluzen1, X Gao, G M Story, L I Anderson, J Kucera, J M Walro.   

Abstract

Deletion of a single copy of the BDNF gene has been shown to affect the nigrostriatal dopaminergic system of young adult BDNF mice. In the present report we evaluated various indices of nigrostriatal dopaminergic function between 9-month-old wild-type (+/+) and heterozygous (+/-) BDNF mutant mice. Performance in a sensorimotor beam walking task was significantly decreased in +/- mice as indicated by increased times required to traverse both a wide (21 mm) and narrow (6 mm) beam. No differences in spontaneous locomotor behavior were observed between the +/+ and +/- mice. Amphetamine-stimulated (5 mg/kg) locomotor behavior was increased to a greater degree in the +/- mice, with the number of movements performed by these mice being significantly greater than their +/+ controls. Corpus striatal dopamine concentrations were significantly greater in the +/- BDNF mice. The absence of any significant differences for dopamine concentrations within the hypothalamus and olfactory bulb of these mice, as well as an absence of any difference in striatal norepinephrine concentrations, suggested a relative specificity of these effects to the corpus striatum. Both the +/- and +/+ mice showed similar reductions in striatal dopamine concentrations in response to a neurotoxic regimen of methamphetamine (20 mg/kg). Collectively these data show increased levels of striatal dopamine concentrations associated with altered behavioral responses involving the nigrostriatal dopaminergic system within the heterozygous BDNF mutant mice. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11421589     DOI: 10.1006/exnr.2001.7698

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  26 in total

Review 1.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging.

Authors:  H A Boger; P Mannangatti; D J Samuvel; A J Saylor; T S Bender; J F McGinty; A M Fortress; V Zaman; P Huang; L D Middaugh; P K Randall; L D Jayanthi; B Rohrer; K L Helke; A-C Granholm; S Ramamoorthy
Journal:  Genes Brain Behav       Date:  2010-10-19       Impact factor: 3.449

3.  BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slices.

Authors:  H Jourdi; L Hamo; T Oka; A Seegan; M Baudry
Journal:  Neuropharmacology       Date:  2009-01-21       Impact factor: 5.250

4.  Aberrant striatal dopamine transmitter dynamics in brain-derived neurotrophic factor-deficient mice.

Authors:  Kelly E Bosse; Francis K Maina; Johnna A Birbeck; Marion M France; Joseph J P Roberts; Michelle L Colombo; Tiffany A Mathews
Journal:  J Neurochem       Date:  2011-12-02       Impact factor: 5.372

5.  5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch; Twum A Ansah
Journal:  Neuropharmacology       Date:  2010-03-31       Impact factor: 5.250

Review 6.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 7.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

8.  Drug-induced activation of dopamine D(1) receptor signaling and inhibition of class I/II histone deacetylase induce chromatin remodeling in reward circuitry and modulate cocaine-related behaviors.

Authors:  Frederick A Schroeder; Krista L Penta; Anouch Matevossian; Sara R Jones; Christine Konradi; Andrew R Tapper; Schahram Akbarian
Journal:  Neuropsychopharmacology       Date:  2008-02-20       Impact factor: 7.853

9.  Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice.

Authors:  Yu Zhao; Michael DeCuypere; Mark S LeDoux
Journal:  Exp Neurol       Date:  2008-01-19       Impact factor: 5.330

10.  Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice.

Authors:  A J Saylor; J F McGinty
Journal:  Genes Brain Behav       Date:  2008-08-04       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.